Gilead’s lenacapavir has been on the market since 2022, when it was approved in the U.S. as Sunlenca for twice-yearly ...
Gilead Sciences, Inc. GILD and partner Merck MRK announced positive data from two late-stage studies, ISLEND-1 and ISLEND-2, ...
The combination of islatravir and lenacapavir targets multiple stages of HIV-1 replication, potentially offering people with ...
Gilead & Merck announce positive topline results from two phase 3 studies evaluating islatravir/lenacapavir, an oral once-weekly HIV treatment: Foster City, California Wednesday, ...
Gilead and Merck announce positive phase 3 results for once-weekly oral islatravir/lenacapavir, demonstrating noninferiority in virologically suppressed HIV.
The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ROME Therapeutics, a biotechnology company harnessing the power of the dark genome for drug development, today announced a new publication in The Proceedings of the ...
The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...
Gilead Sciences, Inc. GILD has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy for treatment and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results